SCHEMBL30135798

SCHEMBL30135798

CN(CC1CCN(c2ccc(C3CCC(=O)NC3=O)cc2F)CC1)C1CCC(NC(=O)OCc2ccccc2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.38
GAA P10253 1/20 0.38
DPP4 P27487 6/20 0.37
DPP7 Q9UHL4 6/20 0.37
KCNH2 Q12809 4/20 0.37
TSHR P16473 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
KDM1A O60341 1/20 0.36
MAOB P27338 1/20 0.36
DDB1 Q16531 1/20 0.35
CRBN Q96SW2 1/20 0.35
GPR55 Q9Y2T6 1/20 0.35
CHRM4 P08173 1/20 0.35
CTSL P07711 1/20 0.34
CTSB P07858 1/20 0.34
CTSK P43235 1/20 0.34
TLR4 O00206 1/20 0.34
ESR1 P03372 1/20 0.34
ADORA2A P29274 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30135834 0.97 ALDH1A1 (0.38) ALDH1A1GAADPP4DPP7KCNH2
SCHEMBL30135779 0.88 CRBN (0.41) GAADDB1CRBNESR1
SCHEMBL25031448 0.88 DDB1 (0.43) DDB1CRBN
SCHEMBL25937176 0.88 DDB1 (0.43) DDB1CRBN
SCHEMBL30135903 0.86 ALDH1A1 (0.40) ALDH1A1GAADPP4DPP7KCNH2
SCHEMBL25301480 0.85 CRBN (0.37) GAADDB1CRBNESR1
SCHEMBL25262031 0.85 CRBN (0.37) GAADDB1CRBNESR1
SCHEMBL25336380 0.82 CRBN (0.37) GAADDB1CRBNESR1
SCHEMBL30981249 0.82 CRBN (0.43) KMT2ADDB1CRBNESR1
SCHEMBL25941035 0.82 CRBN (0.43) KMT2ADDB1CRBNESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11939334-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers UPPTHERA, INC. (KR) 2024-03-26 US disclosed
US-20230242541-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-08-03 US disclosed
EP-4157850-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND Uppthera, Inc. (KR) 2023-04-05 EP disclosed
WO-2023018236-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-02-16 WO disclosed
WO-2023017446-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11939334-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers PLK1, BUB1B, BUB1 ALDH1A1 2752/4885GAA 2669/4885DPP4 3316/4885
US-20230242541-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND PLK1, BUB1B, BUB1 ALDH1A1 4008/4885GAA 2658/4885DPP4 4009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.